MYIA
VRTX icon

Mount Yale Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Mount Yale Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
2,252
+223
+11% +$98.8K 0.02% 554
2026
Q1 		$906K Sell
2,029
-107
-5% -$49.9K 0.02% 547
2025
Q4 		$968K Buy
2,136
+451
+27% +$194K 0.05% 321
2025
Q3 		$660K Buy
1,685
+1,352
+406% +$565K 0.05% 357
2025
Q2 		$148K Buy
+333
New +$153K 0.01% 596
2020
Q4 		– Sell
-1,763
Closed -$480K – 422
2020
Q3 		$480K Buy
1,763
+796
+82% +$220K 0.07% 247
2020
Q2 		$281K Buy
+967
New +$262K 0.05% 271
2018
Q4 		– Sell
-880
Closed -$162K – 778
2018
Q3 		$162K Buy
880
+43
+5% +$7.66K 0.03% 322
2018
Q2 		$142K Buy
837
+219
+35% +$33.9K 0.03% 364
2018
Q1 		$101K Buy
+618
New +$101K 0.02% 450

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Mount Yale Investment Advisors's VRTX Position: Q2 2026 in Review

Mount Yale Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2026, buying an estimated $98.8K and bringing the position to 2,252 shares worth $1.12M. The position accounts for 0.02% of the portfolio, ranked #554.

Mount Yale Investment Advisors first reported a position in VRTX in Q1 2018 and has held it in 10 quarters since. 1,763 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Mount Yale Investment Advisors held 2,252 shares of Vertex Pharmaceuticals worth $1.12M as of Q2 2026.
  • Mount Yale Investment Advisors bought 223 Vertex Pharmaceuticals shares in Q2 2026, an estimated $98.8K.
  • Vertex Pharmaceuticals made up 0.02% of Mount Yale Investment Advisors's portfolio in Q2 2026, its #554 holding.
  • Mount Yale Investment Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 10 quarters since.
  • 1,763 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.